Long-term real costs of a strategy using rituximab as first-line treatment for patients with moderate-to-severe pemphigus: Evaluation from the French healthcare system.

IF 8.4 2区医学 Q1 DERMATOLOGY

Journal of the European Academy of Dermatology and Venereology Pub Date : 2024-12-12 DOI:10.1111/jdv.20497

Billal Tedbirt, Hermance De Mulder, Pascal Joly, Elie Lacroix, Vivien Hébert

引用次数: 0

查看原文本刊更多论文

使用利妥昔单抗作为中重度丘疹性荨麻疹患者一线治疗策略的长期实际成本：法国医疗系统的评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the European Academy of Dermatology and Venereology 医学-皮肤病学

CiteScore

10.70

自引率

8.70%

发文量

874

审稿时长

3-6 weeks

期刊介绍： The Journal of the European Academy of Dermatology and Venereology (JEADV) is a publication that focuses on dermatology and venereology. It covers various topics within these fields, including both clinical and basic science subjects. The journal publishes articles in different formats, such as editorials, review articles, practice articles, original papers, short reports, letters to the editor, features, and announcements from the European Academy of Dermatology and Venereology (EADV). The journal covers a wide range of keywords, including allergy, cancer, clinical medicine, cytokines, dermatology, drug reactions, hair disease, laser therapy, nail disease, oncology, skin cancer, skin disease, therapeutics, tumors, virus infections, and venereology. The JEADV is indexed and abstracted by various databases and resources, including Abstracts on Hygiene & Communicable Diseases, Academic Search, AgBiotech News & Information, Botanical Pesticides, CAB Abstracts®, Embase, Global Health, InfoTrac, Ingenta Select, MEDLINE/PubMed, Science Citation Index Expanded, and others.